StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Veracyte revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Veracyte's revenue for the twelve months ending Jun 30, 2026 was $561.90M, up 17.3% year over year. For fiscal 2025 it was $517.15M, up 16.0% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is $517.15M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$517.15M+16.0%
FY2024Dec 31, 2024$445.76M+23.5%
FY2023Dec 31, 2023$361.05M+21.8%
FY2022Dec 31, 2022$296.54M+35.1%
FY2021Dec 31, 2021$219.51M+86.8%
FY2020Dec 31, 2020$117.48M-2.4%
FY2019Dec 31, 2019$120.37M+30.8%
FY2018Dec 31, 2018$92.01M+27.9%
FY2017Dec 31, 2017$71.95M+10.6%
FY2016Dec 31, 2016$65.09M+31.5%
FY2015Dec 31, 2015$49.50M+29.6%
FY2014Dec 31, 2014$38.19M+74.5%
FY2013Dec 31, 2013$21.88M+88.2%
FY2012Dec 31, 2012$11.63M+339.6%
FY2011Dec 31, 2011$2.65M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$150.32M+15.5%
Q1 FY2026Mar 31, 2026$139.07M+21.5%
Q4 FY2025Dec 31, 2025$140.64M+18.5%
Q3 FY2025Sep 30, 2025$131.87M+13.8%
Q2 FY2025Jun 30, 2025$130.16M+13.8%
Q1 FY2025Mar 31, 2025$114.47M+18.2%
Q4 FY2024Dec 31, 2024$118.63M+20.8%
Q3 FY2024Sep 30, 2024$115.86M+28.6%
Q2 FY2024Jun 30, 2024$114.43M+26.7%
Q1 FY2024Mar 31, 2024$96.84M+17.5%
Q4 FY2023Dec 31, 2023$98.20M+22.3%
Q3 FY2023Sep 30, 2023$90.11M+19.2%
Q2 FY2023Jun 30, 2023$90.32M+24.0%
Q1 FY2023Mar 31, 2023$82.42M+21.6%
Q4 FY2022Dec 31, 2022$80.30M+19.2%
Q3 FY2022Sep 30, 2022$75.59M+25.2%
Q2 FY2022Jun 30, 2022$72.86M+32.2%
Q1 FY2022Mar 31, 2022$67.78M+84.7%
Q4 FY2021Dec 31, 2021$67.34M+95.0%
Q3 FY2021Sep 30, 2021$60.37M+94.0%
Q2 FY2021Jun 30, 2021$55.11M+166.2%
Q1 FY2021Mar 31, 2021$36.70M+17.9%
Q4 FY2020Dec 31, 2020$34.54M+16.2%
Q3 FY2020Sep 30, 2020$31.12M+0.5%
Q2 FY2020Jun 30, 2020$20.70M-31.3%
Q1 FY2020Mar 31, 2020$31.12M+5.4%
Q4 FY2019Dec 31, 2019$29.73M+15.5%
Q3 FY2019Sep 30, 2019$30.97M+32.0%
Q2 FY2019Jun 30, 2019$30.14M+32.5%
Q1 FY2019Mar 31, 2019$29.53M+47.3%
Q4 FY2018Dec 31, 2018$25.75M+31.4%
Q3 FY2018Sep 30, 2018$23.47M+33.9%
Q2 FY2018Jun 30, 2018$22.75M+23.6%
Q1 FY2018Mar 31, 2018$20.04M+22.0%
Q4 FY2017Dec 31, 2017$19.60M+7.3%
Q3 FY2017Sep 30, 2017$17.52M-5.8%
Q2 FY2017Jun 30, 2017$18.41M–
Q1 FY2017Mar 31, 2017$16.43M–
Q4 FY2016Dec 31, 2016$18.26M–
Q3 FY2016Sep 30, 2016$18.60M–

More Veracyte figures

See a number that looks wrong?